What did we learn specifically about the population of patients with post-ACS and T2D who were treated with alirocumab in the ODYSSEY Outcomes Trial?

What did we learn specifically about the population of patients with post-ACS and T2D who were treated with alirocumab in the ODYSSEY Outcomes Trial?

What did we learn specifically about the population of patients with post-ACS and T2D who were treated with alirocumab in the ODYSSEY Outcomes Trial?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Vincent Woo, MD, FRCPC

Vincent Woo, MD, FRCPC

Endocrinology and Metabolism University of Manitoba Principal Investigator Diabetes Research Group John Buhler Research Centre Winnipeg, Manitoba, Canada